When a biotech company starts preparing for clinical trials, one of the questions that often comes up is which pharmacovigilance safety database to implement.
It’s an important decision, but it may not be the first one a company needs to make.
Before comparing systems, companies need to understand their product, their clinical development plans, and what their pharmacovigilance requirements will look like as they progress through development. Without that understanding, it’s easy to focus on selecting a database before knowing when it will actually be needed or what it needs to support.
The right starting point is a roadmap, not a software decision.
The database matters. But the experience behind it matters more.
There are several pharmacovigilance safety databases available, and many are capable of meeting the necessary requirements. The system itself is only one part of the decision.
What matters is understanding what regulations require and how the database fits into the company’s wider clinical, pharmacovigilance, and digital roadmaps. Those requirements will evolve as a product moves from a Phase 1 clinical trial toward commercialization.
This is where experience makes a difference.
If multiple vendors offer the same systems and all claim to have implementation experience, how do you decide who is right for your business?
Dr. Henry Seto, iVigee’s Chief Medical Officer, makes an interesting comparison with surgery. You might have the same tools, the same hospital, and even the same staff, but you would still want the surgeon with the best outcomes for your patient.
The same principle applies to pharmacovigilance. Knowing how to implement a particular database is one thing. Knowing how to plan, manage, and deliver an implementation in the context of a company’s development journey is another.
Why the timing of your safety database matters
Vijeet Goel, iVigee’s Executive Director, Head of Pharmacovigilance Systems, shares two examples that show why planning matters: two clinical-stage companies that approached their safety database requirements very differently.
The first company requested a roadmap at Phase 1. This meant the database could be planned and implemented at the right point in its development, rather than becoming an urgent requirement later.
The second company approached the process just three months before its clinical trial was due to start. Contracting, implementation, and FDA E2B(R3) gateway qualification were all still outstanding.
Both companies needed a safety database. The difference was when they started planning for it.
In the second case, the challenge wasn’t simply selecting the right system. It was fitting everything that needed to happen into an increasingly tight timeframe.
This is why waiting until a database becomes an immediate requirement can create unnecessary pressure. Understanding the regulatory and operational requirements early gives companies a clearer picture of what needs to happen and when.
Start with a pharmacovigilance roadmap
For companies approaching their first clinical trial, choosing a pharmacovigilance safety database doesn’t have to be the starting point.
A basic roadmap can help establish:
- What the product and clinical development plans require.
- When a safety database will be needed.
- How the database fits into the wider clinical, PV, and digital strategy.
- What needs to be considered ahead of implementation, including regulatory requirements and gateway qualification.
The objective isn’t to implement a system earlier than necessary. It’s to understand what will be required, avoid unnecessary delays, and make sure the right solution is ready when the business needs it.
A roadmap doesn’t have to be a major investment, but it can make a significant difference to how smoothly the process unfolds.
At iVigee, we believe the conversation should start with understanding your product and your plans, not simply deciding which database to buy.
If your company is approaching clinical trials and hasn’t established a safety database before, now is a good time to start that conversation.